Recognizing the Strength of Rare Disease Families on Rare Disease Day ??Today, on #Rarediseaseday, we recognize the strength of families affected by rare diseases. For parents, the journey is often filled with uncertainty and hope for better treatments. At Saol Therapeutics, we share that hope. We remain committed to working toward potential new treatment options for Pyruvate Dehydrogenase Complex Deficiency (PDCD). Together, we strive for a future where rare disease patients have more options and more hope. ?? #HopeforPDCD #CureMito #MitoAction #UMDF
关于我们
Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.
- 网站
-
https://www.saolrx.com
Saol Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Roswell，GA
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Rare Disease、CNS、Clinical Development、Pain、Osteoarthritis、Spasticity、Orphan Disease、Mitochondrial Disorders、Biotechnology和Pharmaceuticals
地点
Saol Therapeutics员工
动态
-
Saol Therapeutics is hiring for the position of Director/Sr. Director - Market Access. https://lnkd.in/ecaXD5NK
-
Saol Therapeutics is hiring for the position of Medical Affairs Director. https://lnkd.in/eHmfg_Nb
-
Another key milestone for Saol Therapeutics towards a treatment for PDCD. The FDA granted Priority Review for the SL1009 NDA and has set a goal date of?May 27, 2025, under the Prescription Drug User Fee Act (PDUFA). Full press release can be found on Saolrx.com. https://lnkd.in/egjm42hw
-
A major milestone for Saol Therapeutics! https://lnkd.in/ec-QidMh
-
Saol Therapeutics Announces Positive Topline Results from the SL-1002 RAISE Limb Spasticity Trial https://lnkd.in/emVB7Jg2
-
-
Saol Therapeutics Announces Topline Data from the SL-1002 RAISE Limb Spasticity Trial to be Presented at?Spasticity X https://lnkd.in/e4c4dVj9
-
Leigh syndrome is a progressive, terminal, neurodegenerative disease. Kids lose their abilities to walk, talk, swallow. #leighsyndrome #mitochondrialdisease #mitoawareness
-
-
Today, we remember all those loved ones whom we've lost to #mitochondrialdisease. Light a candle, remember always, and #IlluminateTomorrow for the #mito community.